Empowering Innovation for
Military Medicine and Beyond
Diagnose
Treat
Recovery
Turning breakthrough ideas into scalable medical innovations that revolutionize defense healthcare and improve lives worldwide.
SelasBio works with groundbreaking medical entrepreneurs and technologies overlooked by traditional venture capital by focusing on defense healthcare challenges, providing early funding, and leveraging military use cases to drive scalable societal impact.
Navigating
DoD Pathways
We leverage our team’s expertise and military connections to identify DoD needs, secure first funding, and access first customers through SBIR/STTR and other DoD initiatives.
Transforming Technology Success
Driving the translation of cutting-edge research into market-ready solutions through exceptional productization and commercialization expertise.
Our Portfolio
Leadership / Science
Government
Contact Us
San Francisco | Boston | San Antonio | New York
© SelasBio. All rights reserved.
Over 20 years in leadership, business development and sales growth in pharmaceutical, biotechnology and technology. Passionate about making a difference though innovation that can benefit humankind. Enjoy building and empowering talented teams. Former Army NCO that drives my ability to be agile and execute, as well as take on any challenge in a steadfast way. Father of three sons, which adds daily adventure to my life.
Brad Hamilton is the co-founder and Chief Scientific Officer of SelasBio, where he leads the development and commercialization of technologies across the company portfolio.With more than 25 years of biotechnology leadership experience in drug discovery and cell and gene therapy, Brad has founded and led multiple venture-backed biotechnology companies - developing breakthrough platform technologies in multiplexed orthogonal gene switches, epigenetic modification, RNA interference (RNAi), embryonic and induced pluripotent stem cell (ES/iPSC) derivation and engineering, and blood bioprocessing.Throughout his career, he has led the development of more than 100 life science products with research and clinical applications, contributing to multiple successful company exits with a combined value exceeding $300 million dollars.Brad holds a B.S. in Biology from James Madison University and an M.S. in Biotechnology from the University of Tennessee.
Scientifically-driven biotech entrepreneur and executive focused on building companies and technology in cell and gene therapy and drug discovery, whose leadership has led to three successful exits for VC/PE-backed startups. Thriving at the intersection of science and business and excelling at conversion of novel technologies into products/technologies/services.